Similarly, Sorafenib treatment recruits tumor neutrophil infiltration in animal models as well as HCC patients by inducing the CXCL5 expression in tumor cells via the hypoxia-inducible factor 1-alpha (HIF1α)/nuclear factor-κB (NF-κB) pathway [53]. This evidence concerns the gene HIF1A and hepatocellular carcinoma.